This article was originally published in Start Up
CeMines has a proprietary method of identifying high volumes of auto-antibody profiles simultaneously; these correlate to regulatory patters in cancer cells, the company believes.
You may also be interested in...
Oncologic Inc. hopes to circumvent the heterogeneity of solid tumors with a multi-step process. It will target two independent cellular cancer characteristics-the presence of an endocytosing receptor, and sensitivity to a chemotherapeutic agent; then erect a novel chemical platform throughout the tumor to hold radioactive isotopes in place to kill the entire tumor, not just individual cancer cells.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.